Atopiclair as a new, non-steroidal treatment option for atopic dermatitis patients in Asia. In a study published by Boguniewicz, et al, in the Journal of Pediatrics in 2008, Atopiclair™ was shown to be safe and effective as a monotherapy for the treatment of mild-to-moderate symptoms of atopic dermatitis, with children in the study experiencing complete or almost complete improvement in their symptoms within 22 days5.
At today’s press conference, Invida announced its planned launches of Atopiclair™ across numerous Asia Pacific markets. Invida Korea has a history of providing Korean physicians and patients with access to new therapies,” said Mark Brown, Invida Korea Country Manager. “We are very excited to add Atopiclair™ to our product portfolio in Korea and believe that Atopiclair™ will be a significant treatment to help patients and their families better manage the debilitating symptoms of atopic dermatitis.
Invida will soon also be introducing several other dermatology treatments in the region including Papulex™ for acne management, and Sebclair™ for seborrhoeic dermatitis.
The most widely recognized international dermatology gathering, the 22nd World Congress of Dermatology is being held from May 24-29 at the Coex Convention and Exhibition Center in Seoul, South Korea. Held every four years, the 2011 Congress is hosted by the International League of Dermatological Societies and organized by the Korean Dermatological Association.
About Invida Group Private Limited
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality – the result of which will allow all Invida stakeholders to prosper. This is done through proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.
With more than 3,500 employees in 13 markets in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. Portfolio of proprietary healthcare brands as well as licensed products from emerging and large, multinational biopharmaceutical companies. Partnering is a critical component of Invida’s business model.